Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.51 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL466290 | 0.89 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG | |
| SCHEMBL3623403 | 0.87 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG | |
| SCHEMBL1182129 | 0.82 | PIK3CA (0.69) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL963220 | 0.82 | PIK3CA (0.73) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1497337 | 0.81 | RECQL (0.48) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG | |
| SCHEMBL994553 | 0.80 | PIK3CD (0.48) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG | |
| SCHEMBL993496 | 0.80 | PIK3CD (0.46) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG | |
| SCHEMBL994312 | 0.79 | PIK3CD (0.47) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG | |
| SCHEMBL1089183 | 0.78 | PIK3CD (0.77) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG | |
| SCHEMBL390171 | 0.78 | PIK3CD (0.77) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367663-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CD 39/4885PIK3CA 58/4885PIK3R1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.